Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12Trastuzumab 12Lenalidomide 12durvalumab 11daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has announcements × Mitomycin × Clear all
NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed
71 enrolled 16 charts 1 FDA
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡